Journal of Current Glaucoma Practice

Register      Login

VOLUME 18 , ISSUE 1 ( January-March, 2024 ) > List of Articles

Original Article

Clinical Outcomes of MicroPulse Transscleral Laser Therapy with the Revised P3 Delivery Device

Leticia A Checo, Syril Dorairaj, Isabella V Wagner, Abhimanyu S Ahuja

Keywords : Cohort, Glaucoma, Laser, MicroPulse transscleral cyclophotocoagulation, MicroPulse transscleral laser therapy

Citation Information : Checo LA, Dorairaj S, Wagner IV, Ahuja AS. Clinical Outcomes of MicroPulse Transscleral Laser Therapy with the Revised P3 Delivery Device. J Curr Glaucoma Pract 2024; 18 (1):10-15.

DOI: 10.5005/jp-journals-10078-1427

License: CC BY-NC 4.0

Published Online: 30-03-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Aim: To evaluate the success and safety of MicroPulse transscleral laser therapy (TLT) on intraocular pressure (IOP) reduction in adults with uncontrolled glaucoma using different total treatment durations, sweep velocities, and a number of sweeps utilizing the revised MicroPulse P3 delivery device. Materials and methods: A single-center Institutional Review Board (IRB) approved multiple cohort studies of MicroPulse TLT with the revised MicroPulse P3 delivery device, which was conducted in 61 eyes from 40 adults with uncontrolled glaucoma. Eyes that received 50-second (GI, GII, and GIII) and 60-second (GIV, GV, and GVI) treatment applications between May and October 2020 were reviewed. Each hemisphere received a total of five, four, or three sweeps. The patient's IOP and glaucoma medications were monitored over 12 months follow-up. Qualified success was defined as an IOP of ≤21 mm Hg and/or reduction of ≥20% from baseline at 12 months, with no secondary glaucoma reinterventions. Complete success was defined as meeting the above criteria with no increase in glaucoma medications at 12 months. All eyes requiring a glaucoma surgical intervention were considered a failure. Results: Qualified success was achieved in 83.6% of eyes, while complete success was achieved in 75.4% of eyes. In eyes receiving 50-second applications of five, four, or three sweeps (GI, GII, and GIII), 70, 90, and 91% achieved qualified success, respectively; in eyes receiving 60-second applications of five, four, or three sweeps (GIV, GV, and GVI), 78, 82, and 90% achieved qualified success, respectively. Within each subgroup, mean IOP reductions ranged from 32.8 to 49.4% and were statistically significant (p < 0.008). The failure rate was 16.4%, and at least one eye failed in each subgroup. Conclusions: MicroPulse TLT with the revised MicroPulse P3 delivery device and relatively low total energy levels is safe and effective at lowering IOP. Efficacy appears to increase with longer treatment durations and slower sweep velocities, but statistical differences between age and clinical differences between baseline IOP measurements limit comparison between subgroups. Clinical significance: There is a lack of literature evaluating the safety and IOP-lowering success of the revised MicroPulse P3 delivery device using different total treatment durations, sweep velocities, and number of sweeps.

PDF Share
  1. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet 2004;363(9422):1711–20. DOI: 10.1016/S0140-6736(04)16257-0
  2. Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA 2014;311(18):1901–11. DOI: 10.1001/jama.2014.3192
  3. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006;90(3):262–7. DOI: 10.1136/bjo.2005.081224
  4. Francis BA, Singh K, Lin SC, et al. Novel glaucoma procedures: a report by the American Academy of Ophthalmology. Ophthalmology 2011;118(7):1466–80. DOI: 10.1016/j.ophtha.2011.03.028
  5. Saheb H, Ahmed II. Micro-invasive glaucoma surgery: current perspectives and future directions. Curr Opin Ophthalmol 2012;23(2):96–104. DOI: 10.1097/ICU.0b013e32834ff1e7
  6. Ndulue JK, Rahmatnejad K, Sanvicente C, et al. Evolution of cyclophotocoagulation. J Ophthalmic Vis Res 2018;13(1):55–61. DOI: 10.4103/jovr.jovr_190_17
  7. Pastor SA, Singh K, Lee DA, et al. Cyclophotocoagulation: a report by the American Academy of Ophthalmology. Ophthalmology 2001;108(11):2130–8. DOI: 10.1016/S0161-6420(01)00889-2
  8. Zaarour K, Abdelmassih Y, Arej N, et al. Outcomes of micropulse transscleral cyclophotocoagulation in uncontrolled glaucoma patients. J Glaucoma 2019;28(3):270–275. DOI: 10.1097/IJG.0000000000001174
  9. Varikuti VNV, Shah P, Rai O, et al. Outcomes of micropulse transscleral cyclophotocoagulation in eyes with good central vision. J Glaucoma 2019;28(10):901–905. DOI: 10.1097/IJG.0000000000001339
  10. Shah P, Bhakta A, Vanner EA, et al. Safety and efficacy of diode laser transscleral cyclophotocoagulation in eyes with good visual acuity. J Glaucoma 2018;27(10):874–879. DOI: 10.1097/IJG.0000000000001057
  11. Zemba M, Dumitrescu OM, Vaida F, et al. Micropulse vs. continuous wave transscleral cyclophotocoagulation in neovascular glaucoma. Exp Ther Med 2022;23(4):278. DOI: 10.3892/etm.2022.11207
  12. IRIDEX Corporation MOUNTAIN VIEW, Calif. (2020). IRIDEX Launches Revised MicroPulse P3® Device for Glaucoma [Press release].
  13. IRIDEX Corporation. (2021). MicroPulse Transscleral Laser Therapy International consensus panel of ten glaucoma experts [Video]. YouTube
  14. Grippo TM, Sanchez FG, Stauffer J, et al. MicroPulse(®) transscleral laser therapy - fluence may explain variability in clinical outcomes: a literature review and analysis. Clin Ophthalmol 2021;15:2411–2419. DOI: 10.2147/OPTH.S313875
  15. Sarrafpour S, Saleh D, Ayoub S, et al. Micropulse transscleral cyclophotocoagulation: a look at long-term effectiveness and outcomes. Ophthalmol Glaucoma 2019;2(3):167–171. DOI: 10.1016/j.ogla.2019.02.002
  16. Yelenskiy A, Gillette TB, Arosemena A, et al. Patient outcomes following micropulse transscleral cyclophotocoagulation: intermediate-term results. J Glaucoma 2018;27(10):920–925. DOI: 10.1097/IJG.0000000000001023
  17. Balendiran V, Landreneau J, An J. Micropulse transscleral laser therapy dosimetry utilizing the revised P3 delivery device: a randomized controlled trial. Ophthalmol Glaucoma 2023;6(3):283–290. DOI: 10.1016/j.ogla.2022.09.004
  18. Magacho L, Lima FE, Ávila MP. Double-session micropulse transscleral laser (CYCLO G6) as a primary surgical procedure for glaucoma. J Glaucoma 2020;29(3):205–210. DOI: 10.1097/IJG.0000000000001426
  19. Marchand M, Singh H, Agoumi Y. Micropulse trans-scleral laser therapy outcomes for uncontrolled glaucoma: a prospective 18-month study. Can J Ophthalmol 2021;56(6):371–378. DOI: 10.1016/j.jcjo.2021.01.015
  20. Williams AL, Moster MR, Rahmatnejad K, et al. Clinical efficacy and safety profile of micropulse transscleral cyclophotocoagulation in refractory glaucoma. J Glaucoma 2018;27(5):445–449. DOI: 10.1097/IJG.0000000000000934
  21. Emanuel ME, Grover DS, Fellman RL, et al. Micropulse cyclophotocoagulation: initial results in refractory glaucoma. J Glaucoma 2017;26(8):726–729. DOI: 10.1097/IJG.0000000000000715
  22. Sanchez FG, Peirano-Bonomi JC, Grippo TM. Micropulse transscleral cyclophotocoagulation: a hypothesis for the ideal parameters. Med Hypothesis Discov Innov Ophthalmol 2018;7(3):94–100.
  23. Sanchez FG, Lerner F, Sampaolesi J, et al. Efficacy and safety of Micropulse® transscleral cyclophotocoagulation in glaucoma. Arch Soc Esp Oftalmol (Engl Ed) 2018;93(12):573–579. DOI: 10.1016/j.oftal.2018.08.003
  24. Nguyen AT, Maslin J, Noecker RJ. Early results of micropulse transscleral cyclophotocoagulation for the treatment of glaucoma. Eur J Ophthalmol 2020;30(4):700–705. DOI: 10.1177/1120672119839303
  25. Shazly M, Tarek A. Outcomes of Micropulse Transscleral Cyclophotocoagulation in Medically Uncontrolled Glaucoma. (2017). Presented at: The 26th Annual AGS Meeting; Coronado, CA.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.